Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells.

× No keyword cloud information.

5 in total

Review 1. OCT1 and imatinib transport in CML: is it clinically relevant?

Authors: D B Watkins; T P Hughes; D L White
Journal: Leukemia Date: 2015-07-09 Impact factor: 11.528

2. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

Authors: F J Giles; E Abruzzese; G Rosti; D-W Kim; R Bhatia; A Bosly; S Goldberg; G L S Kam; M Jagasia; W Mendrek; T Fischer; T Facon; U Dünzinger; D Marin; M C Mueller; Y Shou; N J Gallagher; R A Larson; F-X Mahon; M Baccarani; J Cortes; H M Kantarjian
Journal: Leukemia Date: 2010-06-03 Impact factor: 11.528

3. In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.

Authors: Sara Redaelli; Pietro Perini; Monica Ceccon; Rocco Piazza; Roberta Rigolio; Mario Mauri; Frank Boschelli; Athina Giannoudis; Carlo Gambacorti-Passerini
Journal: J Hematol Oncol Date: 2015-07-07 Impact factor: 17.388

4. OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.

Authors: Yeo-Kyeoung Kim; Seung-Shin Lee; Sung-Hoon Jeong; Jae-Sook Ahn; Deok-Hwan Yang; Je-Jung Lee; Myung-Geun Shin; Hyeoung-Joon Kim
Journal: Chonnam Med J Date: 2014-12-17

5. Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.

Authors: Jueqiong Wang; Liu Lu; Chung H Kok; Verity A Saunders; Jarrad M Goyne; Phuong Dang; Tamara M Leclercq; Timothy P Hughes; Deborah L White
Journal: Haematologica Date: 2017-02-02 Impact factor: 9.941

5 in total